- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on KRAS G12C in Singapore
Total 4 results
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
Novartis PharmaceuticalsRecruitingAdvanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,MelanomaNetherlands, Korea, Republic of, Spain, Taiwan, Japan, Italy, Canada, United States, Singapore
-
Novartis PharmaceuticalsRecruitingCarcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Colorectal Cancer | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal | Non-Small Cell Lung Carcinoma | KRAS G12C Mutant Solid TumorsKorea, Republic of, Spain, Belgium, United States, France, Germany, Italy, Singapore
-
Novartis PharmaceuticalsRecruitingCarcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung | Cancer of the Lung | KRAS G12C Mutant Solid Tumors | Carcinoma, ColorectalUnited States, Japan, Australia, Germany, Italy, Spain, Canada, Denmark, Korea, Republic of, Taiwan, Belgium, Hong Kong, China, France, Singapore, Netherlands